Emactuzumab
A monoclonal antibody used in cancer treatment
| Emactuzumab | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Emactuzumab is a monoclonal antibody designed for the treatment of certain types of cancer. It specifically targets the colony-stimulating factor 1 receptor (CSF1R), which is involved in the regulation of macrophage activity. By inhibiting this receptor, Emactuzumab can modulate the tumor microenvironment, potentially reducing tumor growth and metastasis.
Mechanism of Action[edit | edit source]
Emactuzumab binds to the CSF1R, a receptor found on the surface of macrophages and other cells of the immune system. CSF1R is a key regulator of macrophage proliferation and survival. By blocking this receptor, Emactuzumab reduces the number of tumor-associated macrophages (TAMs), which are often involved in promoting tumor growth and suppressing anti-tumor immune responses.
Clinical Applications[edit | edit source]
Emactuzumab is primarily investigated for its use in treating solid tumors, particularly those that are characterized by a high infiltration of TAMs. It has shown promise in early clinical trials for conditions such as tenosynovial giant cell tumor (TGCT), a rare and locally aggressive tumor.
Administration and Dosage[edit | edit source]
Emactuzumab is administered via intravenous infusion. The dosage and frequency of administration depend on the specific clinical protocol and the condition being treated. Patients receiving Emactuzumab are monitored for potential side effects, including infusion-related reactions and changes in blood cell counts.
Side Effects[edit | edit source]
Common side effects of Emactuzumab include fatigue, nausea, and edema. More serious adverse effects can include cytopenias, liver enzyme abnormalities, and infusion-related reactions. Patients are closely monitored during treatment to manage these potential side effects.
Research and Development[edit | edit source]
Emactuzumab is currently under investigation in various clinical trials to assess its efficacy and safety in different cancer types. Research is ongoing to better understand its role in modulating the tumor microenvironment and its potential combination with other immunotherapies.
Related pages[edit | edit source]
Emactuzumab
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
